Skip to main content
SpringerLink
Log in

Mechanisms and Management of Proteinuria in Kidney Transplant Patients

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Proteinuria is a common complication occurring after kidney transplantation. It is associated with an increased risk of renal failure and patient death. Treatment with ACE inhibitors or angiotensin receptor antagonists (blockers) has been shown to reduce proteinuria after kidney transplantation, as well as improve both graft and patient survival. An increase in proteinuria has been observed in some patients after initiation of sirolimus therapy. Although the mechanism of this remains unclear, high proteinuria at baseline and poor renal function at baseline have been identified as potential risk factors for the development of proteinuria after conversion to sirolimus. Initiation of sirolimus therapy is not recommended in patients with early histological indicators of glomerular damage; however, in patients with healthy grafts, sirolimus may prevent future glomerulosclerosis. Early treatment with an ACE inhibitor and sirolimus, prior to the appearance of glomerular changes, may result in better outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, et al. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004 Jun; 19 Suppl. 3: iii47–51

    Article  PubMed  Google Scholar 

  2. Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001 Aug 15; 72(3): 438–44

    Article  PubMed  CAS  Google Scholar 

  3. Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al. Proteinuria is an independent risk factor of cardiovascular disease in renal transplant patient. Transplant Proc 2002 Feb; 34(1): 367

    Article  PubMed  CAS  Google Scholar 

  4. Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005 Sep; 5(9): 2281–8

    Article  PubMed  CAS  Google Scholar 

  5. First MR, Vaidya PN, Maryniak RK, et al. Proteinuria following transplantation. Correlation with histopathology and outcome. Transplantation 1984 Dec; 38(6): 607–12

    CAS  Google Scholar 

  6. Vathsala A, Verani R, Schoenberg L, et al. Proteinuria in cyclosporine-treated renal transplant recipients. Transplantation 1990 Jan; 49(1): 35–41

    Article  PubMed  CAS  Google Scholar 

  7. Chung J, Park SK, Park JS, et al. Glomerulonephritis is the major cause of proteinuria in renal transplant recipients: histopathologic findings of renal allografts with proteinuria. Clin Transplant 2000 Oct; 14(5): 499–504

    Article  PubMed  CAS  Google Scholar 

  8. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006 Nov; 6(11): 2535–42

    Article  PubMed  CAS  Google Scholar 

  9. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005 Jul; 5(7): 1748–56

    Article  PubMed  CAS  Google Scholar 

  10. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006 Nov 15; 82(9): 1153–62

    Article  PubMed  Google Scholar 

  11. Oberbauer R, Segoloni G, Campistol JM, et al. on behalf of the Rapamune Maintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005 Jan; 18(1): 22–8

    CAS  Google Scholar 

  12. Letavernier E, Pe’raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005 Nov 15; 80(9): 1198–203

    Article  PubMed  CAS  Google Scholar 

  13. van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006 Oct; 70(7): 1355–7

    Article  PubMed  Google Scholar 

  14. Ruiz JC, Diekmann F, Campistol JM, et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study. Transplant Proc 2005 Nov; 37(9): 3833–5

    Article  PubMed  CAS  Google Scholar 

  15. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006 Nov; 21(11): 3252–7

    Article  PubMed  CAS  Google Scholar 

  16. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004 Nov; 4(11): 1869–75

    Article  PubMed  CAS  Google Scholar 

  17. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006 Feb; 21(2): 488–93

    Article  PubMed  CAS  Google Scholar 

  18. Sennesael JJ, Bosmans JL, Bogers JP, et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005 Dec 15; 80(11): 1578–85

    Article  PubMed  CAS  Google Scholar 

  19. Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006 Aug 15; 82(3): 368–74

    CAS  Google Scholar 

  20. Barama A, Wang Y, Barama SN, et al. Peak VEGF expression in renal tissue is associated with proteinuria in 5/6 nephrectomized rats receiving sirolimus [abstract no. 2539]. Program and abstracts of the World Transplant Congress 2006; 2006 Jul 22–27; Boston (MA)

  21. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005 Nov 10; 353(19): 2088–9

    Article  PubMed  CAS  Google Scholar 

  22. Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimusassociated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006 Feb; 6(2): 429–33

    Article  PubMed  CAS  Google Scholar 

  23. Traindl O, Falger S, Reading S, et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993 Jun; 55(6): 1309–13

    Article  PubMed  CAS  Google Scholar 

  24. Montanaro D, Gropuzzo M, Tulissi P, et al. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration. Transplant Proc 2004 Apr; 36(3): 692–4

    Article  PubMed  CAS  Google Scholar 

  25. Lufft V, Kliem V, Hamkens A, et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant 1998 Oct; 12(5): 409–15

    PubMed  CAS  Google Scholar 

  26. Zoja C, Corna D, Rottoli D, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002 May; 61(5): 1635–45

    Article  PubMed  CAS  Google Scholar 

  27. Verseput GH, Provoost AP, Braam BB, et al. Angiotensinconverting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat. J Am Soc Nephrol 1997 Feb; 8(2): 249–59

    PubMed  CAS  Google Scholar 

  28. Dominguez-Gil B, Ortiz M, Sierra MP, et al. Losartan reduces massive proteinuria in kidney transplant patients: a pilot study. Transplant Proc 2002 Feb; 34(1): 368–9

    Article  PubMed  CAS  Google Scholar 

  29. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006 Mar; 17(3): 889–99

    Article  PubMed  CAS  Google Scholar 

  30. Artz MA, Hilbrands LB, Borm G, et al. Blockade of the reninangiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004 Nov; 19(11): 2852–7

    Article  Google Scholar 

  31. Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant 2007 Mar–Apr; 21(2): 277–84

    Article  PubMed  Google Scholar 

  32. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342(3): 145–53

    Article  PubMed  CAS  Google Scholar 

  33. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. LIFE Study Group. Lancet 2002 Mar 23; 359(9311): 995–1003

    Article  PubMed  CAS  Google Scholar 

  34. Wright Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. African American Study of Kidney Disease and Hypertension Study Group. JAMA 2002 Nov 20; 288(19): 2421–31

    CAS  Google Scholar 

Download references

Acknowledgements

The author would like to thank Dr Cathryn Jarvis, Dr Isabella Steffensen and Science & Medicine Canada for their editorial assistance in preparing this review. This work was supported by an unrestricted educational grant from Wyeth Canada. Dr Barama reports no conflicts of interest.

Author information

Authors and Affiliations

  1. Surgery and Transplantation, University of Montreal, Montreal, Quebec, Canada

    Azemi A. Barama

Authors
  1. Azemi A. Barama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Azemi A. Barama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barama, A.A. Mechanisms and Management of Proteinuria in Kidney Transplant Patients. Drugs 68 (Suppl 1), 33–39 (2008). https://doi.org/10.2165/00003495-200868001-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868001-00005

Keywords

Search

Navigation